SC-236
| SC-236
|
|---|
SC-236 is a selective cyclooxygenase-2 (COX-2) inhibitor that has been studied for its potential use in treating inflammation and pain. COX-2 inhibitors are a class of drugs that specifically target the COX-2 enzyme, which is responsible for the synthesis of pro-inflammatory prostaglandins.
Mechanism of Action[edit]
SC-236 works by selectively inhibiting the COX-2 enzyme, thereby reducing the production of pro-inflammatory prostaglandins. This action helps to alleviate inflammation and pain without affecting the COX-1 enzyme, which is important for maintaining the protective lining of the stomach and regulating blood platelets.
Pharmacokinetics[edit]
The pharmacokinetics of SC-236 involve its absorption, distribution, metabolism, and excretion. SC-236 is absorbed into the bloodstream after oral administration and is distributed throughout the body. It is metabolized primarily in the liver and excreted through the kidneys.
Clinical Applications[edit]
SC-236 has been investigated for its potential use in treating conditions such as arthritis, cancer, and other inflammatory diseases. Its selective inhibition of COX-2 makes it a promising candidate for reducing inflammation with fewer gastrointestinal side effects compared to non-selective NSAIDs.
Research and Development[edit]
Research on SC-236 has focused on its efficacy and safety profile. Studies have shown that SC-236 can effectively reduce inflammation and pain in animal models. However, further clinical trials are necessary to fully understand its potential benefits and risks in humans.
Side Effects[edit]
As with other COX-2 inhibitors, potential side effects of SC-236 may include cardiovascular risks, such as an increased risk of heart attack or stroke. Gastrointestinal side effects are generally less common compared to non-selective NSAIDs.
Regulatory Status[edit]
As of the latest updates, SC-236 is still under investigation and has not been approved for clinical use by major regulatory agencies such as the FDA or EMA.
Also see[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
